Technical Analysis for ADMP - Adamis Pharmaceuticals Corporation

Grade Last Price % Change Price Change
grade F 1.5 -0.66% -0.01
ADMP closed down 0.66 percent on Friday, May 24, 2019, on 1.13 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMP trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -0.66%
New Downtrend Bearish -0.66%

Older signals for ADMP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.
Medicine Health Biopharmaceutical Manufacturing Medical Specialties Infectious Diseases Pharmaceutical Products Prostate Cancer Respiratory Therapy Asthma Allergy Dosage Forms Chronic Obstructive Pulmonary Disease Smoking Cessation Emergency Treatment Inhaler Metered Dose Inhaler Rhinitis
Is ADMP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 24 The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
May 23 The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut
May 21 ARRY, DY, QD and DQ among notable midday movers
May 21 Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
May 20 Adamis: Cuts Op-Ex And Prepares For 'Zimhi' Approval
May 20 Microcaps mostly among midday movers
May 14 Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
May 10 Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT
May 10 Adamis Pharmaceuticals' (ADMP) CEO Dennis Carlo on Q1 2019 Results - Earnings Call Transcript
May 9 Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates
See more ADMP news...
Indicators
Indicator Value
52 Week High 5.1
52 Week Low 1.49
Average Volume 421,071
200-Day Moving Average 2.6533
50-Day Moving Average 2.0146
20-Day Moving Average 1.915
10-Day Moving Average 1.749
Average True Range 0.1364
ADX 26.72
+DI 10.6589
-DI 29.3055
Chandelier Exit (Long, 3 ATRs ) 1.9108
Chandelier Exit (Short, 3 ATRs ) 1.8992
Upper Bollinger Band 2.3311
Lower Bollinger Band 1.4989
Percent B (%b) 0.0
BandWidth 43.456919
MACD Line -0.1396
MACD Signal Line -0.0942
MACD Histogram -0.0455
Fundamentals Value
Market Cap 47.03 Million
Num Shares 31.4 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -1.72
Price-to-Sales 14.86
Price-to-Book 4.42
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.67
Resistance 3 (R3) 1.68 1.64 1.64
Resistance 2 (R2) 1.64 1.60 1.63 1.63
Resistance 1 (R1) 1.57 1.57 1.55 1.56 1.62
Pivot Point 1.53 1.53 1.52 1.52 1.53
Support 1 (S1) 1.46 1.49 1.44 1.45 1.38
Support 2 (S2) 1.42 1.46 1.41 1.37
Support 3 (S3) 1.35 1.42 1.36
Support 4 (S4) 1.34